Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

27 June 2015: Clinical Research  

Evaluation of the Effect of Modafinil on Cognitive Functions in Patients with Idiopathic Hypersomnia with P300

Mehmet Yaman ABEG , Fatıma Karakaya BDEF , Tuğçe Aydin BF , Hasan Mayda BD , Hail İbrahim Güzel BDF , Dilek Kayaalp B

DOI: 10.12659/MSM.893448

Med Sci Monit 2015; 21:1850-1855

0 Comments

Abstract

BACKGROUND: Modafinil is a well-tolerated psychostimulant drug with low addictive potential that is used to treat patients with narcolepsy and other excessive sleepiness. Whereas favorable effects of modafinil on cognitive functions have been shown in a large number of studies, there are very few reports presenting the effects of modafinil electrophysiologically. The aim of this study was to investigate the effects of modafinil on auditory P300 latency and amplitude electrophysiologically.

MATERIAL AND METHODS: Eighteen patients (age range: 16–48 years) with a diagnosis of idiopathic hypersomnia (IH) were included in the present study. As a standard treatment, 200 mg/day modafinil was administered to each patient. The P300 auditory test was performed for each patient before and at the end of 1 week of modafinil treatment.

RESULTS: After 1 week of modafinil treatment, mean P300 latencies (at all electrode sites) were significantly lower than the latencies before the treatment (P values for Fz, Cz and Pz recording sites were 0.039, 0.002, and 0.004, respectively). An increase in the P300 amplitudes was detected only at the Fz recording site, but not at Cz or Pz recording sites (P values for Fz, Cz, and Pz recording sites were 0.014, 0.100, and 0.05, respectively).

CONCLUSIONS: One week of modafinil treatment improved the cognitive performance, alertness, and executive functions in IH patients. Our electrophysiologically obtained findings provide further confirmation for previous reports in which modafinil has been shown to exert favorable effects on cognitive performance, alertness, and executive functions.

Keywords: Benzhydryl Compounds - therapeutic use, Adolescent, Cognition - drug effects, Event-Related Potentials, P300, Hypersomnolence, Idiopathic - psychology, Wakefulness-Promoting Agents - therapeutic use, young adult

Background

Idiopathic hypersomnia (IH) is characterized by chronic, daily, excessive daytime sleepiness despite normal sleep. Excessive daytime sleepiness (EDS) has been linked to several conditions, including sleep deprivation, use of drugs or psychoactive substances, psychiatric or medical disorders, respiratory problems (such as obstructive sleep apnea), and structural lesions (such as stroke or head injury) [1]. Since it has been distinguished from narcolepsy, IH has been defined based on small cases series, with a variety of clinical forms [2]. IH patients have decreased wakefulness and increased naps during the day. Patients may also have prolonged difficulty in waking with automatic behavior, as well as confusion and repeated returns to sleep, a symptom named “sleep drunkenness”. IH was identified relatively recently by Bedric Roth. He described patients not only with EDS per se (monosymptomatic) but also with prolonged night sleep who exhibit sleep drunkenness on waking (polysymptomatic) [3].

The 2nd edition of the International Classification of Sleep Disorders (ICSD-2) defines IH with long sleep time (LST) and IH without long sleep time (w/o LST). According to the ICSD-2, diagnosis of these hypersomnias can only be made when patients have both subjective excessive daytime sleepiness occurring almost daily for at least 3 months and a mean sleep latency of less than 8 min on the Multiple Sleep Latency Test (MSLT). A diagnosis of IH with LST requires prolonged nocturnal sleep time (more than 10 h) documented by interviews, actigraphy and/or sleep logs, great difficulty waking up either in the morning or at the end of a nap, and less than 2 sleep-onset rapid eye movements. In contrast, patients with IH w/o LST have normal nocturnal sleep (greater than 6 h but less than 10 h) [4]. Although cognitive insufficiency has not been reported in IH, concentration difficulty, distractibility, and momentary memory problems may be expected [5].

Modafinil, a 2-[(diphenyl methyl) sulfinyl] acetamide derivative (also known as Provigil or Modiodal), has recently been introduced for the treatment of excessive sleepiness associated with narcolepsy [6]. Although the exact mechanism of action is unknown, it appears that modafinil promotes vigilance by indirect activation of the frontal cortex via the hypothalamus and/or the tuberomammillary nucleus [7–9]. It may also inhibit dopamine-like receptors and GABA release [10–15]. Moreover, modafinil action has also been associated with increased glutamatergic, adrenergic, and histaminergic activity [16]. Hence, although modafinil has been studied in a very limited number of studies, use of modafinil for IH treatment has been increasing recently. This increased research interest is occurring because modafinil has recently been demonstrated to increase thalamocortical activity and cognitive functions, and to have favorable effects on attention, memory, and learning [17–25].

Event-related potentials (ERP) are cerebral responses associated with various psychological events or cognitive functions such as recognition of certain stimuli, and an objective parameter reflecting cognitive functions [26–28]. Previous studies have shown that, while P300 latency measures evaluation speed of a given stimulus, amplitude measures working memory functions [28–30]. Among ERP, auditory P300 is the most used for measured electrophysiologically cognitive functions. P300 is one of the most prominent positive peaks, occurring around 300 ms after the infrequently presented to respond by a certain task in the ‘odd-ball paradigm’ [31]. Particularly event related potentials which are a good indicator of cognitive function, are useful for analysis of brain physiology during cognitive function, and provide information about temporal function. Although in many studies, alterations in the P300 latency and amplitude have been demonstrated in neurological and psychiatric diseases, the effects of a cortex activating agent, modafinil, on P300 has not been investigated electrophysiologically yet [22,32–38].

Whereas positive effect of modafinil on cognitive functions has been shown in many studies, there are very few reports presenting the effects of modafinil electrophysiologically [17–24]. Therefore, we sought to investigate the effects of modafinil on P300 latency and amplitude electrophysiologically in patients who were diagnosed as IH clinically and for whom modafinil treatment has been initiated.

Material and Methods

Patient selection

PATIENT SELECTION:

We identified patients who admitted to our neurology or psychiatry outpatient clinics at Afyon Kocatepe University Medical Faculty, January 2010 to June 2011, diagnosed with IH, and in whom modafinil treatment was initiated. Among them, 18 patients who decided to participate in the study were included. All patients were fully informed about the purpose of the study and the procedures to be employed. All patients were asked not to use any other medication that may affect their cognitive functions except modafinil during the study period of 1 week. We excluded patients with mental retardation, hearing problems, any history of substance abuse or alcohol addiction that would prevent them from taking the test. The study protocol was approved by the Ethics Committee of Afyon Kocatepe University, and all patients participated voluntarily with written informed consent.

ERP RECORDING TECHNIQUES:

Initially, baseline auditory ERPs were recorded in patients with IH. Then, the same test was repeated after 1 week of modafinil treatment. Reproducibility and reliability of the P300 latency measurements have been clearly established by short- and long-term studies in normal controls after repeated recordings. On each session, P300 amplitude and latency were measured. In all patients, the P300 recordings were obtained after an optimal overnight sleep before the breakfast (at 9:00 am). All measurements were performed by the same electrophysiologist at the Department of Neurology, who was blinded to patient treatment status.

RECORDING CONDITIONS:

Electroencephalographic (EEG) activity was recorded at the frontal (Fz), central (Cz), and parietal (Pz) electrode sites of the 10/20 international system using Ag/AgCl electrodes, affixed with electrode paste and tape, with an impedance of 10 k Ohm or less. The reference electrode was attached to the right earlobe and the ground electrode was attached to the left earlobe.

STIMULUS SET-UP:

In this study, Keypoint G4 workstation equipment (Denmark) auditory oddball stimulus set-up was used. A standard stimulus of 90 dB SPL intensity and 1000 Hz, and a target stimulus of 90dB SPL intensity and 2000 Hz frequency pure sound were used. Target stimuli constituted of 20% (n=60) of 300 total stimuli and were given in between standard stimuli in a random manner. Patients were asked not to move, not to talk, not to blink too much, and to look at a fixed point in the middle of the computer screen. They were asked to press the button whenever they heard random target stimuli applied in between the auditory stimuli.

PROCEDURE:

Prior to experimental procedures, a 5-min adaptation period was given for the patient and EEG was calibrated. Following the attachment of electrodes, patients were placed on an adjustable chair in an isolated room adjacent to the recording room. Subjects were instructed to sit quietly with open eyes, follow the stimuli carefully, and to try to determine rare tones of 1000 Hz frequency. The amplitudes were measured peak-to-peak. The amplitude and latency measurements were compared before and after 1 week of modafinil treatment.

STATISTICAL METHODS:

Statistical analysis was performed by using SPSS 10.0 software for Windows. All data are presented as mean ±S.D. The Wilcoxon test and paired t-test were used for the statistical analysis. P<0.05 was considered significant.

Results

In total, 18 patients were evaluated in the study (8 males, 10 females). Mean age was 23.0±6.7 (min: 16, max: 48). The grand means of the auditory P300 at all electrode sites for the 2 timepoints (before and after treatment) are presented in Figure 1. The latencies of the P300 component measured at the Fz, Cz, and Pz electrode sites were assessed separately. After 1 week of modafinil treatment, mean P300 latencies (at all electrode sites) had decreased significantly compared to latencies before the treatment (P values 0.039, 0.002, and 0.004, respectively, Table 1). After 1 week of modafinil treatment but mean P300 amplitudes were increased. A significant increase at the Fz electrode was detected after 1 week of modafinil treatment but mean P300 amplitudes were decreased and a significant increase at the Fz electrode was detected (Fz: 0.014, Cz: 0.100 and Pz: 0.05, Table 1).

Discussion

This study shows that treatment with modafinil (200 mg/day) has positive effects on auditory P300. We observed a shortening of P300 latency at Fz, Cz, and Pz sites after 1 week of modafinil treatment compared to pre-treatment. Moreover, an increase only at the Fz site was detected at the P300 amplitudes of the same sites and there was no amplitude change at the Cz and Pz sites. In line with earlier reports, our results show that modafinil has positive effects on cognitive functions. P300 ERP application (particularly P300 ERP latency) is a well-established neurophysiological approach in any disease where cognitive functions are impaired [39]. Our method is relatively simple, safe, non-invasive, and reproducible compared to other metabolic and structural studies of the brain. P300 latency has been related to the speed of stimulus evaluation [40]. Moreover, P300 latency has been reported to exhibit a good correlation with the conventional neurophysiological tests (e.g., the Wechsler Adult Intelligence Scale score and Wechsler memory scale) for the assessment of cognitive performance [41–43]. The effects of modafinil on cognitive functions have been explored in a number of earlier studies. Although P300 latency is a test that is widely used for the evaluation of cognitive performance in many diseases, the effect of modafinil on P300 latency and amplitude has been investigated in very few studies [44].

In an earlier animal study, Shuman et al. showed the effects of modafinil on 3 types of memory (spatial memory, context fear memory, and cued fear memory) and found specific enhancements of hippocampus-dependent spatial memory and contextual fear memory. They found that the effect of modafinil on memory is similar to other conventional psychostimulants, but is more specific on hippocampus-dependent memory [45]. Similarly, in a placebo controlled, double-blind study on healthy young volunteers, Natalie et al. demonstrated that 200 mg of modafinil facilitated rapid shifts of attention [23]. An extensive studies performed in this field was by Wesensten et al., who showed that modafinil at a dose of 200 mg/day significantly improved performance in verbal fluency, flexibility, and originality compared to placebo as measured by the Torrence Test of Creative Thinking-Verbal. Furthermore, they found that modafinil also improved performance in the Wisconsin Card Sorting Test (which measures executive function) and Haylings Sentence Completion (which measures the ability to inhibit verbal responses) [46]. In a 2002 study, the same group demonstrated that modafinil at the doses of 200 mg and 400 mg significantly improved the cognitive performance and alertness compared to placebo, at a similar level to 600 mg of caffeine, in people who were subjected to sleep deprivation [47]. Muller et al. evaluated the effects of modafinil 200 mg versus placebo on a numeric working memory task, a delayed matching-to-sample task, letter cancellation, and trail-making using a double-blind crossover design. Modafinil decreased errors on the numeric working memory task, particularly for the most difficult condition [19]. In addition, Turner et al. showed that modafinil increased higher-order performance in non-sleep-deprived volunteers [48]. In general, the above-mentioned and similar studies clearly present the beneficial effect of modafinil on alertness, cognitive performance, and memory. However, in some other studies a similar effect was not observed for modafinil. For example, Randall et al. found that modafinil was not superior over placebo in tests of long-term memory, executive function, visuospatial and constructional ability, or category fluency. In that study, the authors reported that the effect of modafinil on the improvement of cognitive performance is limited in non-sleep-deprived subjects [49]. Similarly, in a study on 18 healthy non-sleep-deprived adults, Baransky et al. emphasized that modafinil’s effect on cognitive performance was not as expected, and they suggested further investigation [22].

Based on our data, we found that 200 mg/day of modafinil treatment for a period of 1 week had positive effects on cognitive performance, alertness, and executive function. Our results are in accordance with previous reports on the effect of modafinil on cognitive functions and alertness. The mechanism of action of modafinil remains controversial. Data from animal experiments suggests that modafinil may exert its effect by direct activation of the tuberomammillary nucleus and the hypocretin neurons of the perifornical area [50]. Currently, an indirect stimulation by noradrenaline (particularly, via α1-adrenoreceptor) and other arousal-enhancing neurotransmitters (e.g., serotonin, histamine, and acetylcholine) seems to be the most likely mechanism of action of modafinil [51,52]. Some researchers also found that glutamate increases and GABA inhibits the effects of modafinil [15]. When all these effects of modafinil are considered together, it would not be a surprise that it has a shortening effect on P300 latency and increasing effect on Fz P300 amplitude at all 3 sites (Fz, Cz, and Pz) and it increases cognitive performance, alertness, and executive functions. In earlier animal studies, modafinil has been shown to increase thalamocortical activity [17]. Joo et al. found that single-dose modafinil in healthy non-sleep-deprived volunteers increases cerebral blood flow in the thalamus, brainstem, insular cortex, and limbic system, which are related to arousal, attention, executive function, and emotional functions, respectively [53].

Conclusions

This study demonstrates that 1 week of modafinil treatment causes a shortening of P300 latency at all 3 sites (Fz, Cz, and Pz) and increases Fz P300 amplitude in patients with IH. This result is an electrophysiological confirmation of previous studies in which modafinil has been shown to improve cognitive performance, alertness, and executive functions. This study is one of the first in this field, and needs to be confirmed with neuropsychological tests and more subjects.

Referencees

1. Cyrille V, Isabella A, Idiopathic hypersomnia with and without long sleep Time: a controlled series of 75 patients: Sleep, 2009; 32; 753-59, pmid: 19544751

2. Kirstie NA, Smantha P, Linda DS, Idiopathic hypersomnia: a study of 77 cases: Sleep, 2007; 30; 1274-81, pmid: 17969461

3. Adie WJ, Idiopathic narcolepsy: a disease sui generis; with remarks on the mechanism of sleep: Brain, 1926; 49; 257-306

4. : International Classification of Sleep Disorders: diagnostic and coding manual, 2005, Westchester, IL, American Academy of Sleep Medicine

5. Sasai T, Inoue Y, Komada Y, Comparison of clinical characteristics among narcolepsy with or without cataplexy and idiopathic hypersomnia without long sleep time, focusing on HLA-DRB1*1501/DQB1*0602 finding: Sleep Med, 2009; 10; 961-66, pmid: 19410508

6. US Modafinil Multicenter Study Group, Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: Neurology, 2000; 54; 1166-75, pmid: 10720292

7. Lin JS, Hou Y, Jouvet M, Potential brain neuronal targets for amphetamine-methylphenidate-,and modafinil-induced wakeful-ness, evidenced by c-fos immunochemistry in the cat: Proc Natl Acad Sci USA, 1996; 93; 14128-33, pmid: 8943072

8. Chemelli RM, Willie JT, Sinton CM, Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation: Cell, 1999; 98; 437-51, pmid: 10481909

9. Shammell TE, Estabrooke IV, McCarthy MT, Hypothalamic arousal regions are activated during modafinil-induced wakefulness: J Neurosci, 2000; 20; 8620-28, pmid: 11069971

10. Korotkova TM, Klyuch BP, Ponomarenko AA, Modafinil inhibits rat midbrain dopaminergic neurons through D2-like receptors: Neuropharmacology, 2007; 52; 626-33, pmid: 17070873

11. Tanganelli S, Fuxe K, Ferraro L, Inhibitory effects of the psychoactive drug modafinil on gamma-aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea-pig. Possible involvement of 5-hydroxytryptamine mechanisms: Naunyn-Schmiedebergs Arch Pharmacol, 1992; 345; 461-65, pmid: 1620245

12. Tanganelli S, Perez de la Mora M, Ferraro L, Modafinil and cortical gamma-aminobutyric acid outflow. Modulation by 5-hydroxytryptamine neurotoxins: Eur J Pharmacol, 1995; 273; 63-71, pmid: 7737319

13. Ferraro L, Tanganelli S, O’Connor WT, The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: possible involvement of the serotonergic 5-HT3 receptor: Neurosci Lett, 1996; 220; 5-8, pmid: 8977135

14. Ferraro L, Antonelli T, O’Connor WT, The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission: Neurosci Lett, 1998; 253; 135-38, pmid: 9774168

15. Ferraro L, Antonelli T, Tanganelli S, The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABA A receptor blockade: Neuropsychopharmacology, 1999; 20; 347-56

16. Ballon JS, Feifel D, A systematic review of modafinil: Potential clinical uses and mechanisms of action: Clin Psychiatry, 2006; 67; 554-66

17. Urbano FJ, Leznik E, Llinas RR, Modafinil enhances thalamocortical activity by incresing neuronal electronic coupling: Proc Natl Acad Sci USA, 2007; 30; 12554-59, pmid: 17640897

18. Golicki D, Bala MM, Niewada M, Wierzbicka A, Modafinil for Narcolepsy: systematic review and meta-analysis: Med Sci Monit, 2010; 16(8); RA177-86, pmid: 20671626

19. Müler U, Steffenhagen N, Regenthal R, Bublak P, Effects of modafinil on working in memory processes in humans: Psychopharmacology, 2004; 177; 161-69, pmid: 15221200

20. Randall DC, Shneerson JM, File SE, Cognitive effects of modafinil in student volunteers may depend on IQ: Pharmacol Biochem Behav, 2005; 82; 133-39, pmid: 16140369

21. Wesensten NJ, Belenky G, Kautz MA, Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine: Psychopharmacology, 2002; 159; 238-47, pmid: 11862356

22. Baranski JV, Pigeau R, Dinich P, Jacobs I, Effects of modafinil on cognitive: Hum Psychopharmacol, 2004; 19; 323-32, pmid: 15252824

23. Natalie LM, Faddy K, Kezi E, Modafinil improves rapid shifts of attention: Psychopharmacology, 2009; 202; 487-95, pmid: 19031073

24. Delia CR, Nicola LF, John MS, Sandra EF, The cognitive-enhancing properties of modafinil are limited in non-sleep-deprived middle-aged volunteers: Pharmacol Biochem Behavior, 2004; 77; 547-55

25. Ortiz AT, Pérez-Serrano JM, Zaglul ZC, P300 clinical utility in major depression: Actas Esp Psiquiatr, 2002; 30; 1-6, pmid: 11893284

26. Lee B, Park KS, Kang DH, Generators of the gamma-band activities in response to rare and novel stimuli during the auditory oddball paradigm: Neurosci Lett, 2007; 413; 210-15, pmid: 17208373

27. Duncan CC, Barry RJ, Connolly JF, Event- related potentials in clinical research: Guidelines for eliciting, recording, and quantifying mismatch negativity, P300, and N400: Clin Neurophysiol, 2009; 120; 1883-908, pmid: 19796989

28. Vesco KK, Bone RC, Ryan JC, Polich J, P300 in young and elderly subjects: auditory frequency and intensity effects: Electroencephalogr Clin Neurophysiol, 1993; 88; 302-8, pmid: 7688285

29. Gandleman-Marton R, Theitler J, Chaim SB, Rabey JM, Delayed post-ictal event-related potentials do not differentiate between generalized tonic-clonic seizures and syncope: Seizure, 2007; 16; 454-58, pmid: 17412616

30. Polich J, Kok A, Cognitive and biological determinants of P300: an integrative review: Biol Psychol, 1995; 41; 103-46, pmid: 8534788

31. Johnson JR, On the neual generators of the P300 component of the event-related potential: Psychophysiology, 1993; 30; 90-97, pmid: 8416066

32. Zukov I, Ptacek R, Kozelek P, Brain wave P300: a comperative study of various forms of criminal activity: Med Sci Monit, 2009; 15(7); CR349-54, pmid: 19564824

33. Pascalis VD, Varriale V, Matteoli A, Intelligence and P3 components of the event-related potential elicited during an auditory discrimination task with masking: Intelligence, 2008; 36; 35-47

34. Polich J, Ehlers CL, Otis S, P300 latency reflects the degree ofcognitive decline in dementing illness: Electroencephogr Clin Neurophysiol, 1986; 63; 38-44

35. Johnson JR, Barnhardt J, Zhu J, The contribution of executive processes to deceptive responding: Neuropsychologia, 2004; 42; 878-901, pmid: 14998703

36. Fischer C, Luaute J, Nemoz C, Improved prediction of awakening or nonawakening from severe anoxic coma using treebased classification analysis: Crit Care Med, 2006; 34; 1520-24, pmid: 16557163

37. Holt LE, Raine A, Pa G, P300 topography in Alzheimer’s disease: Psychophysiology, 1995; 32; 257-65, pmid: 7784534

38. Soysal A, Ataklı D, Atay T, Auditory event-related potentials (P300) in partial and generalized epileptic patients: Seizure, 1999; 8; 107-10, pmid: 10222303

39. Polich J, Meta-analysis of P300 normative aging studies: Psychophysiology, 1996; 33; 334-53, pmid: 8753933

40. Gurrera RJ, Salisbury DF, O’Donnell BF, Auditory P3 indexes personality traits and cognitive function in healthy men and women: Psychiatry Res, 2005; 133; 215-28, pmid: 15740997

41. De Pascalis V, Varriale V, Matteoli A, Intenlligence and P3 components of the event-related potential elicited during an auditory discrimination task with masking: Intelligence, 2008; 38; 35-47

42. Wechsler D: Wechsler Abbreviated Scale of Intelligence, 1999, San Antonio, TX, The Psychological Corporation

43. Stige S, Fjell AM, Smith L, The development of visual P3a and P3b: Dev Neuropsychol, 2007; 32; 563-84, pmid: 17650994

44. Wechsler D: Wechsler Intelligence Scale for children, fourth edition (WISC-IV), 2003, San Antonio, TX, The Psychological Corporation

45. Shuman T1, Wood SC, Anagnostaras SG, Modafinil and memory: effects of modafinil on Morris water maze learning and pavlovian fear conditioning: Behav Neurosci, 2009; 123; 257-66, pmid: 19331449

46. Nancy JW, William DK, Thomas JB, Performance and alertness effects of caffein, dextroamphetamine, and modafinil during sleep deprivation: J Sleep Res, 2005; 14; 225-66

47. Nancy JW, Gregory B, Mary AK, Maintaining alertrness and performance during sleep deprivation: modafinil versus caffeine: Psychopharmacology, 2002; 159; 238-47, pmid: 11862356

48. Danielle CT, Trevor WR, Luke C, Cognitive enhancing effects of modafinil in healthy volunteers: Psychopharmacology, 2003; 165; 260-69, pmid: 12417966

49. Delia CR, Aparna V, Punam B, Does Modafinil enhance cognitive performance in young volunteers who are not sleep-deprived?: J Clin Psychopharmacol, 2005; 25; 175-79, pmid: 15738750

50. Scammell TE, Estabrooke IV, McCarthy MT, Hypothalamic arousal regions are activated during modafinil-induced wakefulness: J Neurosci, 2000; 15; 8620-28, pmid: 11069971

51. Ulrich M, Nikolai S, Ralf R, Peter P, Effect of modafinil on working memory process in humans: Psychopharmacology, 2004; 177; 161-69, pmid: 15221200

52. Lin JS, Roussel B, Akaoka H, Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat: Brain Res, 1992; 591; 319-26, pmid: 1359924

53. Joo EY, Tae WS, Jung KY, Hong SB, Cerebral blood flow changes in man by wake-promoting drug, modafinil: a randomized double blind study: J Sleep Res, 2008; 17; 82-88, pmid: 18275558

In Press

Clinical Research  

Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...

Med Sci Monit In Press; DOI: 10.12659/MSM.951027  

Clinical Research  

Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...

Med Sci Monit In Press; DOI: 10.12659/MSM.950516  

Review article  

Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A Review

Med Sci Monit In Press; DOI: 10.12659/MSM.951283  

Clinical Research  

Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 Adults

Med Sci Monit In Press; DOI: 10.12659/MSM.950938  

Most Viewed Current Articles

17 Jan 2024 : Review article   10,187,196

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

13 Nov 2021 : Clinical Research   3,708,487

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

0:00

14 Dec 2022 : Clinical Research   2,341,643

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research   706,524

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750